Drugmaker Zydus Lifesciences Limited has announced plans to launch its Semaglutide Injection (15 mg/3 ml) in India on the very first day the patent expires.
The move is being seen as a major development in the treatment of Type 2 Diabetes and obesity, two conditions that are rising rapidly across the country.
Semaglutide is a GLP-1 receptor agonist, a class of medicines that has changed how doctors manage blood sugar levels and body weight.
Globally, these medicines are widely prescribed because they not only help control diabetes but also support weight loss.
However, the cost of therapy has remained a concern for many patients, especially in India, where long-term treatment expenses can be difficult to manage.
With the patent expiry opening the market to domestic companies, Zydus’ Day-1 launch signals an aggressive strategy.
The company aims to offer a more affordable and convenient option to Indian patients who need long-term therapy for chronic metabolic diseases.
THREE BRAND NAMES FOR THE INDIAN MARKET
Zydus will market its semaglutide injection under three brand names: SEMAGLYN TM, MASHEMA TM and ALTERME TM. The product will be available in a 15 mg/3 ml strength and is designed to meet the needs of patients with Type 2 Diabetes Mellitus and obesity.
The company’s leadership has described the launch as part of its patient-centric innovation strategy, focusing not only on the medicine itself but also on how it is delivered.
WHAT MAKES ZYDUS’ SEMAGLUTIDE DIFFERENT?
The biggest difference lies in the delivery system.
Currently, available semaglutide therapies often require patients to buy separate single-dose pens as their dosage increases over time.
This process, known as dose titration, means patients may need to purchase multiple pens during the course of their treatment.
Zydus has developed an adjustable, reusable single-pen device. This means:
- Patients can select different dose strengths using the same pen
- There is no need to buy multiple pens during dose increases
- The overall cost of therapy may come down
- Treatment becomes more convenient
The company has exclusive rights to this device in India. The pen is capable of delivering all approved strengths required for treating Type 2 Diabetes and obesity.
FOCUS ON AFFORDABILITY AND LONG-TERM ADHERENCE
GLP-1 therapy is often prescribed for long periods, sometimes lifelong. In such cases, the cost of repeated devices can become a burden. By introducing a reusable pen, Zydus aims to reduce recurring device costs.
Convenience also plays an important role in chronic disease management. When treatment is easier to follow, patients are more likely to stay consistent. Better adherence usually leads to better health outcomes.
Speaking on the development, Dr Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said the launch reflects the company’s commitment to innovation focused on patients.
He said the company is not just bringing a critical therapy to market but is also trying to improve the standard of care. According to him, simplifying treatment through a new delivery mechanism could help patients stick to their therapy and achieve better long-term results.
WHY SEMAGLUTIDE MATTERS
Semaglutide works by mimicking a natural hormone called GLP-1, which helps regulate blood sugar levels and appetite.
It improves insulin secretion, reduces glucagon release, and slows down stomach emptying. As a result, patients often see improved blood sugar control and gradual weight reduction.
Globally, semaglutide has become one of the most talked-about treatments for both diabetes and obesity. With rising rates of both conditions in India, access to affordable versions could significantly impact public health.
MARKET IMPACT AND WHAT COMES NEXT
The entry of Zydus on the first day of patent expiry shows how competitive the market is expected to become. More domestic players may also launch their own versions, potentially leading to price competition.
If priced competitively, Zydus’ semaglutide injection could expand access to advanced diabetes and obesity treatment for thousands of Indian patients who previously found it too expensive.
For many patients managing lifelong conditions, a combination of affordability, convenience, and innovation may prove to be the real game changer.
